GlaxoSmithKline, the world’s second-biggest drugmaker, said it agreed to invest $25 million over five years in the Harvard Stem Cell Institute for a collaboration to develop new treatments. London-based Glaxo (NYSE: [[ticker:GSK]]) said the collaboration will spur research at Harvard and at least four affiliated hospitals to study neuroscience, cancer, diabetes, obesity and musculoskeletal diseases. “We have carefully chosen the Boston biomedical community to collaborate with on this important venture. It has the highest concentration of leading stem cell scientists,” GSK’s head of drug discovery, Patrick Vallance, said in a statement.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
